세계의 엡타코그 알파(rFVIIa) : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Eptacog Alfa (rFVIIa) was estimated to be worth US$ 1401 million in 2024 and is forecast to a readjusted size of US$ 1925 million by 2031 with a CAGR of 4.1% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Eptacog Alfa (rFVIIa) cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

In 2024, the global production of Eptacog Alfa (rFVIIa) will be 512 grams, with an average price range of around US$2,731 per mg.

Eptacog Alfa (rFVIIa) is a recombinant activated coagulation factor used to control bleeding or prevent bleeding during surgery and invasive procedures. It is indicated for a variety of patient populations, including patients with congenital hemophilia who have inhibitors to coagulation factor VIII or IX (>=5 BU), patients with congenital hemophilia who are expected to have a strong immune response to coagulation factor VIII/IX replacement therapy, patients with acquired hemophilia, patients with congenital coagulation factor VII deficiency, and patients with thrombocytopenia accompanied by GP IIb/IIIa and/or HLA antibodies who are refractory or have an inadequate response to platelet transfusions.

The global Eptacog Alfa (rFVIIa) market is dominated by a handful of key players: Novo Nordisk's original product, NovoSeven(R), has become a global benchmark thanks to its widespread clinical application; LFB SA's Sevenfact(R)/Cevenfacta(R) offer differentiated alternatives for patients; GENERIUM's Coagil-VII(R), launched in Russia, improves accessibility there and in the Commonwealth of Independent States (CIS); AryoGen Pharmed's AryoSeven(R) provides an economically viable solution in the Middle East; and Chia Tai Tianqing Pharmaceutical Group, China's first domestically produced rFVIIa product, received approval for marketing in 2025, filling a domestic market gap. With the joint development of these brands, rFVIIa is driving global hemostatic treatments from a "brand-name" model to a diversified supply, significantly improving patient accessibility and clinical outcomes.

This report aims to provide a comprehensive presentation of the global market for Eptacog Alfa (rFVIIa), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Eptacog Alfa (rFVIIa) by region & country, by Type, and by Application.

The Eptacog Alfa (rFVIIa) market size, estimations, and forecasts are provided in terms of sales volume (kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (rFVIIa).

Market Segmentation

By Company

• Novo Nordisk
• LFB SA
• GENERIUM
• AryoGen Pharmed
• Chia Tai Tianqing Pharmaceutical Group

Segment by Type

• Prefilled Syringe
• Vial

Segment by Application

• Congenital Hemophilia
• Acquired Hemophilia
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Eptacog Alfa (rFVIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Eptacog Alfa (rFVIIa) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Eptacog Alfa (rFVIIa) in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Eptacog Alfa (rFVIIa) Product Introduction
• 1.2 Global Eptacog Alfa (rFVIIa) Market Size Forecast
  • 1.2.1 Global Eptacog Alfa (rFVIIa) Sales Value (2020-2031)
  • 1.2.2 Global Eptacog Alfa (rFVIIa) Sales Volume (2020-2031)
  • 1.2.3 Global Eptacog Alfa (rFVIIa) Sales Price (2020-2031)
• 1.3 Eptacog Alfa (rFVIIa) Market Trends & Drivers
  • 1.3.1 Eptacog Alfa (rFVIIa) Industry Trends
  • 1.3.2 Eptacog Alfa (rFVIIa) Market Drivers & Opportunity
  • 1.3.3 Eptacog Alfa (rFVIIa) Market Challenges
  • 1.3.4 Eptacog Alfa (rFVIIa) Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Eptacog Alfa (rFVIIa) Players Revenue Ranking (2024)
• 2.2 Global Eptacog Alfa (rFVIIa) Revenue by Company (2020-2025)
• 2.3 Global Eptacog Alfa (rFVIIa) Players Sales Volume Ranking (2024)
• 2.4 Global Eptacog Alfa (rFVIIa) Sales Volume by Company Players (2020-2025)
• 2.5 Global Eptacog Alfa (rFVIIa) Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Eptacog Alfa (rFVIIa) Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Eptacog Alfa (rFVIIa) Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Eptacog Alfa (rFVIIa)
• 2.9 Eptacog Alfa (rFVIIa) Market Competitive Analysis
  • 2.9.1 Eptacog Alfa (rFVIIa) Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Eptacog Alfa (rFVIIa) Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eptacog Alfa (rFVIIa) as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Prefilled Syringe
  • 3.1.2 Vial
• 3.2 Global Eptacog Alfa (rFVIIa) Sales Value by Type
  • 3.2.1 Global Eptacog Alfa (rFVIIa) Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Eptacog Alfa (rFVIIa) Sales Value, by Type (2020-2031)
  • 3.2.3 Global Eptacog Alfa (rFVIIa) Sales Value, by Type (%) (2020-2031)
• 3.3 Global Eptacog Alfa (rFVIIa) Sales Volume by Type
  • 3.3.1 Global Eptacog Alfa (rFVIIa) Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Eptacog Alfa (rFVIIa) Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Eptacog Alfa (rFVIIa) Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Eptacog Alfa (rFVIIa) Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Congenital Hemophilia
  • 4.1.2 Acquired Hemophilia
  • 4.1.3 Others
• 4.2 Global Eptacog Alfa (rFVIIa) Sales Value by Application
  • 4.2.1 Global Eptacog Alfa (rFVIIa) Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Eptacog Alfa (rFVIIa) Sales Value, by Application (2020-2031)
  • 4.2.3 Global Eptacog Alfa (rFVIIa) Sales Value, by Application (%) (2020-2031)
• 4.3 Global Eptacog Alfa (rFVIIa) Sales Volume by Application
  • 4.3.1 Global Eptacog Alfa (rFVIIa) Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Eptacog Alfa (rFVIIa) Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Eptacog Alfa (rFVIIa) Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Eptacog Alfa (rFVIIa) Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Eptacog Alfa (rFVIIa) Sales Value by Region
  • 5.1.1 Global Eptacog Alfa (rFVIIa) Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Eptacog Alfa (rFVIIa) Sales Value by Region (2020-2025)
  • 5.1.3 Global Eptacog Alfa (rFVIIa) Sales Value by Region (2026-2031)
  • 5.1.4 Global Eptacog Alfa (rFVIIa) Sales Value by Region (%), (2020-2031)
• 5.2 Global Eptacog Alfa (rFVIIa) Sales Volume by Region
  • 5.2.1 Global Eptacog Alfa (rFVIIa) Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Eptacog Alfa (rFVIIa) Sales Volume by Region (2020-2025)
  • 5.2.3 Global Eptacog Alfa (rFVIIa) Sales Volume by Region (2026-2031)
  • 5.2.4 Global Eptacog Alfa (rFVIIa) Sales Volume by Region (%), (2020-2031)
• 5.3 Global Eptacog Alfa (rFVIIa) Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 5.4.2 North America Eptacog Alfa (rFVIIa) Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 5.5.2 Europe Eptacog Alfa (rFVIIa) Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Eptacog Alfa (rFVIIa) Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 5.7.2 South America Eptacog Alfa (rFVIIa) Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Eptacog Alfa (rFVIIa) Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Eptacog Alfa (rFVIIa) Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Eptacog Alfa (rFVIIa) Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Eptacog Alfa (rFVIIa) Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 6.3.2 United States Eptacog Alfa (rFVIIa) Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Eptacog Alfa (rFVIIa) Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 6.4.2 Europe Eptacog Alfa (rFVIIa) Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Eptacog Alfa (rFVIIa) Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 6.5.2 China Eptacog Alfa (rFVIIa) Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Eptacog Alfa (rFVIIa) Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 6.6.2 Japan Eptacog Alfa (rFVIIa) Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Eptacog Alfa (rFVIIa) Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 6.7.2 South Korea Eptacog Alfa (rFVIIa) Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Eptacog Alfa (rFVIIa) Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Eptacog Alfa (rFVIIa) Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Eptacog Alfa (rFVIIa) Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Eptacog Alfa (rFVIIa) Sales Value, 2020-2031
  • 6.9.2 India Eptacog Alfa (rFVIIa) Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Eptacog Alfa (rFVIIa) Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Novo Nordisk
  • 7.1.1 Novo Nordisk Company Information
  • 7.1.2 Novo Nordisk Introduction and Business Overview
  • 7.1.3 Novo Nordisk Eptacog Alfa (rFVIIa) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Novo Nordisk Eptacog Alfa (rFVIIa) Product Offerings
  • 7.1.5 Novo Nordisk Recent Development
• 7.2 LFB SA
  • 7.2.1 LFB SA Company Information
  • 7.2.2 LFB SA Introduction and Business Overview
  • 7.2.3 LFB SA Eptacog Alfa (rFVIIa) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 LFB SA Eptacog Alfa (rFVIIa) Product Offerings
  • 7.2.5 LFB SA Recent Development
• 7.3 GENERIUM
  • 7.3.1 GENERIUM Company Information
  • 7.3.2 GENERIUM Introduction and Business Overview
  • 7.3.3 GENERIUM Eptacog Alfa (rFVIIa) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 GENERIUM Eptacog Alfa (rFVIIa) Product Offerings
  • 7.3.5 GENERIUM Recent Development
• 7.4 AryoGen Pharmed
  • 7.4.1 AryoGen Pharmed Company Information
  • 7.4.2 AryoGen Pharmed Introduction and Business Overview
  • 7.4.3 AryoGen Pharmed Eptacog Alfa (rFVIIa) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 AryoGen Pharmed Eptacog Alfa (rFVIIa) Product Offerings
  • 7.4.5 AryoGen Pharmed Recent Development
• 7.5 Chia Tai Tianqing Pharmaceutical Group
  • 7.5.1 Chia Tai Tianqing Pharmaceutical Group Company Information
  • 7.5.2 Chia Tai Tianqing Pharmaceutical Group Introduction and Business Overview
  • 7.5.3 Chia Tai Tianqing Pharmaceutical Group Eptacog Alfa (rFVIIa) Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Chia Tai Tianqing Pharmaceutical Group Eptacog Alfa (rFVIIa) Product Offerings
  • 7.5.5 Chia Tai Tianqing Pharmaceutical Group Recent Development

8 Industry Chain Analysis

• 8.1 Eptacog Alfa (rFVIIa) Industrial Chain
• 8.2 Eptacog Alfa (rFVIIa) Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Eptacog Alfa (rFVIIa) Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Eptacog Alfa (rFVIIa) Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer